Type Diabetes Clinical Trials 2024
Here are the 6 most popular medical studies for type 2 diabetes
Behavioral Intervention
Small Steps for Big Changes Program for Prediabetes
This trial seeks to evaluate changes in HbA1c, diet, weight and waist circumference in people with prediabetes who have taken part in a 6-week diet & exercise program (SSBC).
Procedure
Laparoscopic Gastric Bypass for Type 2 Diabetes
The aim of this study is to evaluate the effect of Roux-en-y gastric bypass (RYGB) in controlling diabetes in subjects with mild obesity (BMI 26-35). The primary endpoint will be the reduction of HbA1c (< 7%), a standard measure of diabetes control; the secondary endpoints will be changes blood sugar , vitamin levels, insulin, c-peptide, and lipids levels, as well as retinal eye examinations, urinalysis to assess kidney function, carotid ultrasound as a marker of cardiovascular function, and alterations in diabetic medications. Fifty subjects with medically documented type 2 Diabetes Mellitus (T2DM) with BMIs between 26 and 35 will undergo standard laparoscopic RYGB. Prior and after surgery, the subjects will undergo a clinical evaluation in regard to the primary and secondary endpoints listed. The pre-surgery evaluation is directed toward establishing the existence of diabetes related complications prior to surgery. After surgery subjects will be closely monitored for complications and required changes in their diabetes management. Repeat assessments will be made at 1, 3, 6, and 12 months and at two years.
DPP-4 Inhibitor
Sitagliptin for Type 2 Diabetes
Background: Incretin hormones are hormones produced by the gut in response to food intake. These hormones help the body to control the metabolism of glucose (sugar). In particular, two incretin hormones (GLP-1 and GIP) cause the pancreas to secrete more insulin in response to high blood glucose levels. This helps the body to metabolize the glucose more effectively, lowering blood sugar levels. In addition to their effects on the pancreas, GLP-1 and GIP have effects on other tissues, including the brain, gut, fat cells and bone. A new class of oral drugs developed for the treatment of type 2 diabetes mellitus (T2DM) called DPP-4 inhibitors increases levels of the active forms of GLP-1 and GIP in the body by preventing their breakdown. This study tests whether a medicine in this class called sitagliptin (Januvia), which is commonly used to treat T2DM, affects markers of bone turnover in patients with T2DM. The hypothesis is that treatment with sitagliptin will increase markers of bone formation and decrease markers of bone resorption during a mixed meal, by enhancing active circulating levels of GLP-1, GIP and GLP-2. Methods: To address this question we will recruit patients with T2DM whose diabetes is controlled with either diet+exercise or with metformin (another medicine commonly used to treat T2DM). Subjects will undergo measurement of body fat and bone mineral density by DEXA scanning and a 3-hour mixed meal test. During the mixed meal test blood samples will be taken to measure how much GLP-1 and GIP are produced. Markers of bone formation will also be measured in blood samples obtained during the mixed meal test. Subjects will then be randomly assigned to 8 weeks of treatment with either sitagliptin (100 mg/day) or matching placebo (an inactive tablet that does not contain medication). Subjects will be seen 4 weeks after commencing treatment to assess safety and tolerability. After 8 weeks of treatment the meal test will be repeated. Subjects will then be washed off of their initial treatment (sitagliptin or placebo) for 1 week (that is, they will receive no study medication during this period). After the washout period, they will commence a second 8-week period of treatment with the other study medication (that is, if they received sitagliptin initially, they will receive placebo during period 2 and vice-versa). At the end of period 2, subjects will undergo a third mixed meal test with measurement of GLP-1, GIP and markers of bone turnover. Significance: Recent studies suggest that oral antidiabetic medications of the thiazolidinedione class, such as rosiglitazone (Avandia) and pioglitazone (Actos), may weaken bones, increasing the risk of fractures in older women with diabetes. The proposed study will test whether drugs of the DPP-4 inhibitor class, such as sitagliptin (Januvia), have beneficial effects on bone turnover by increasing the activity of GLP-1 and GIP. Results of this pilot study may suggest the need to perform longer-term studies to determine whether DPP-4 inhibitors increase bone mineral density and reduce the risk of fractures in patients with diabetes.
Popular filter options for type 2 diabetes trials
T2D Clinical Trials
View 78 T2D medical studies.
Continuous Glucose Monitoring System
Continuous Glucose Monitoring for Type 2 Diabetes
This trial tests if using a CGM system is safe and effective for managing diabetes compared to current methods. Patients wear sensors & come to the study site 4 times & make 2 phone calls over 12 wks. Results will tell if CGM reduces risk of low blood sugar in T2D.
Behavioural Intervention
Virtual Consults for Cardio-Renal-Metabolic Conditions
This trial will study 200 patients hospitalized with heart failure, CKD, and/or type 2 diabetes to see if virtual consults improve medication use. Patients' clinician teams will be assigned at random to receive the consult or not.
Metabolic Syndrome Clinical Trials
View 16 Metabolic Syndrome medical studies.
Behavioural Intervention
Morning and Evening Exercise for Sedentary Lifestyle
"This trial aims to study how exercising at different times of the day affects metabolism, sleep, and other factors. Participants will go through screening visits, follow specific diets, complete exercise conditions in a random order
Procedure
Surgical vs. Lifestyle Interventions for Type 2 Diabetes
This trial is being done to compare the effectiveness of two types of bariatric surgery against an intensive lifestyle intervention in promoting weight loss and improvements in Type 2 diabetes in moderately obese patients.
Insulin
Humulin +2 More for Diabetes
The purpose of this study is to determine if restoring normal metabolic function in patients with type 1 or type 2 diabetes can improve the impact of the consequences of diabetic complications on the overall health and quality of life for diabetic patients.Patients are treated once per week with intensive bolus intravenous insulin delivery mimicking normal insulin secretions in a non diabetic individual. Baseline and periodic diagnostic tests are performed and questionnaires completed to evaluate and monitor progress and outcomes.
Behavioural Intervention
Ketogenic diet for Obesity
The purpose of the study is to evaluate the efficacy and safety of ketogenic diet (KD) treatment of (i) obesity, (ii) type 2 diabetes mellitus and (iii) obstructive sleep apnea (OSA) in patients with obesity and Type 2 DM and in patients with obesity and/or OSA. This will be a randomized, open-label three arm controlled study comparing weight loss in obese participants with type 2 diabetes and/or obstructive sleep apnea treated for 9 months with 3:1 [fat]:[protein+carbohydrate] ratio, 1600 kcal/day diet (Group A) with weight loss in participants treated with orlistat 120 mg TID and lifestyle intervention consisting of dietary advice, recommended caloric goal of 1600 kcal/day (Group B), and in participants treated with only lifestyle intervention consisting of dietary advice, recommended caloric goal of 1600 kcal/day (Group C).
Phase 3 Type 2 Diabetes Clinical Trials
View 96 phase 3 type 2 diabetes medical studies.
Amylin Analog
Pramlintide for Type 2 Diabetes
The hypothesis of the study is that those obese patients with type 2 diabetes mellitus who do not respond to the FDA approved dose of 120 mcg of pramlintide (Symlin®) 3 times daily with expected glucose control require higher than FDA approved dosage. The primary objective of the study is to determine whether higher doses of pramlintide (Symlin®) in patients with type 2 diabetes mellitus control glucose better than the FDA approved dose of 120 mcg three times daily. The secondary objectives include proving whether higher dose pramlintide (Symlin®) is more efficacious in causing weight loss and reduction in waist circumference than standard dose pramlintide (Symlin®),to determine whether blood levels of certain hormones correlate with need for higher dose therapy,and to determine whether or not the rate of common adverse effects exceeds the maximum FDA approved pramlintide (Symlin®) dose of 120 mcg three times daily.
Insulin
Humulin +2 More for Diabetes
The purpose of this study is to determine if restoring normal metabolic function in patients with type 1 or type 2 diabetes can improve the impact of the consequences of diabetic complications on the overall health and quality of life for diabetic patients.Patients are treated once per week with intensive bolus intravenous insulin delivery mimicking normal insulin secretions in a non diabetic individual. Baseline and periodic diagnostic tests are performed and questionnaires completed to evaluate and monitor progress and outcomes.
Behavioral Intervention
Lifestyle counseling +1 More for Type 2 Diabetes
Patients with Type 2 Diabetes randomly allocated to the intervention arm (health coaching + smartphone-based health promotion software) will have significantly better Hemoglobin A1c levels at 6 months post-intervention than patients with Type 2 Diabetes allocated to the control arm (health coaching alone).
Glucagon-like peptide-1 receptor agonist
Semaglutide for Chronic Kidney Disease in Type 2 Diabetes
This trial is testing whether semaglutide can help slow down the progression of kidney disease in people with type 2 diabetes. Participants will be given either semaglutide or a placebo, and neither they nor the researchers will know who is receiving which. The study will last for 3-5 years.
Ertugliflozin for Pediatric Type 2 Diabetes
This trial will study whether ertugliflozin is safe and effective in children with Type 2 Diabetes who are already taking metformin and/or insulin. The goal is to see if ertugliflozin can help lower HbA1C levels more than placebo after 24 weeks.
Type 2 Diabetes Clinical Trials With No Placebo
View 96 type 2 diabetes medical studies that do not have a placebo group.
Continuous Glucose Monitoring System
Continuous Glucose Monitoring for Type 2 Diabetes
This trial tests if using a CGM system is safe and effective for managing diabetes compared to current methods. Patients wear sensors & come to the study site 4 times & make 2 phone calls over 12 wks. Results will tell if CGM reduces risk of low blood sugar in T2D.
Behavioural Intervention
Virtual Consults for Cardio-Renal-Metabolic Conditions
This trial will study 200 patients hospitalized with heart failure, CKD, and/or type 2 diabetes to see if virtual consults improve medication use. Patients' clinician teams will be assigned at random to receive the consult or not.
View More Type 2 Diabetes Trials
See another 72 medical studies focused on type 2 diabetes.
Frequently Asked Questions
Introduction to type 2 diabetes
What are the top hospitals conducting type 2 diabetes research?
In the ongoing battle against type 2 diabetes, several hospitals are leading the charge in conducting groundbreaking clinical trials. One such institution is the Novo Nordisk Investigational Site in Los Angeles, where researchers are currently engaged in six active trials focused on this prevalent condition. Although they have not yet completed any previous trials specifically for type 2 diabetes, their dedication to finding innovative treatments is evident. Similarly committed to advancing diabetes research is the Iowa Diabetes and Endocrinology Research Center located in West Des Moines. With five ongoing clinical trials dedicated to type 2 diabetes, this center has yet to complete any prior studies pertaining directly to this disease but stands as a beacon of hope for patients seeking novel treatment options.
Heading south to Dallas, we find another institution at the forefront of type 2 diabetes research: The Dallas Diabetes Research Center embarks on five active clinical trials aimed solely at tackling this chronic illness. While they may not have conducted any past studies relevant to type 2 diabetes thus far, their current endeavors demonstrate an unwavering commitment towards improving patient outcomes and quality of life.
Meanwhile, Novo Nordisk Investigational Site in San Antonio also joins forces with its Los Angeles counterpart by initiating five concurrent clinical trials that address various aspects of type 2 diabetes management. As with their previous counterparts discussed above, no prior specific investigations can be attributed solely toward combating Type- II-diabetes.On a similar note,Rainier Clinical Research Center located Renton places emphasis on fighting against Type-II-diabetes by focusing four ongoing trial projects while lacking previously recorded explicit undertakings
These hospitals stand as beacons of collaboration between medical professionals and brave individuals who volunteer for these trials; united by a common goal - changing lives through scientific advancements and breakthroughs against one of today's most pressing health concerns
Which are the best cities for type 2 diabetes clinical trials?
When it comes to type 2 diabetes clinical trials, several cities have emerged as leading centers for research and development. San Antonio, Texas, boasts 17 active trials investigating treatments like Cohort A: AMG 133 and HTD1801. Las Vegas, Nevada follows closely with 16 ongoing studies focused on Orforglipron and Empagliflozin. Additionally, Los Angeles, California contributes to the advancement of diabetes care through its 15 active trials exploring Semaglutide and Tirzepatide among others. These cities offer individuals with type 2 diabetes access to cutting-edge clinical trials that pave the way for potential breakthroughs in treatment options.
Which are the top treatments for type 2 diabetes being explored in clinical trials?
Clinical trials are actively investigating several promising treatments for type 2 diabetes. Standout contenders include:
- Semaglutide: A drug showing great potential, currently being explored in six ongoing clinical trials.
- Sotagliflozin: Another treatment gaining attention, with involvement in four active trials.
- Dapagliflozin: This medication is also under investigation and has appeared in three ongoing studies. With each trial, researchers strive to uncover new therapies that can effectively manage type 2 diabetes and improve the lives of patients worldwide.
What are the most recent clinical trials for type 2 diabetes?
Recent clinical trials offer new insights and potential treatments for individuals with type 2 diabetes. One notable study is investigating Orforglipron Dose 2, reaching Phase 3 to assess its effectiveness in managing the condition. Another trial focuses on receiving treatment specifically tailored for type 2 diabetes, aiming to improve patients' overall well-being. Additionally, an intriguing Phase 1 trial explores the use of Active THC as a potential therapeutic option. These ongoing studies reflect the scientific community's commitment to finding innovative solutions that could transform the lives of those living with type 2 diabetes into healthier and more manageable ones.
What type 2 diabetes clinical trials were recently completed?
Several clinical trials focusing on type 2 diabetes have recently concluded, bringing potential advancements in treatment for this prevalent metabolic disorder. These recent completions include a trial investigating the efficacy of an innovative medication sponsored by Johnson & Johnson. Additionally, Novo Nordisk completed a study evaluating a new insulin formulation specifically designed to address the needs of individuals with type 2 diabetes. These exciting developments highlight ongoing efforts to improve management options and enhance quality of life for those living with this chronic condition.